Associated Papers
Comprehensive mutational scanning of EGFR reveals TKI sensitivities of extracellular domain mutants.
Hayes TK et al.
Nature Communications, 2024
38548752 (PubMed )
Supplement: 41467_2024_45594_MOESM4_ESM.xlsx › All
Simulation analysis of EGFR mutation detection: Oncomine Dx target test and AmoyDx panel impact on lung cancer treatment decisions.
Hirotsu Y et al.
Scientific Reports, 2024
38238401 (PubMed )
Supplement: 41598_2024_52006_MOESM3_ESM.xlsx › Sheet1
Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter Study.
Ji J et al.
Jto Clinical and Research Reports, 2023
Structure-Guided Strategies of Targeted Therapies for Patients with EGFR-Mutant Non-Small Cell Lung Cancer.
Du Z et al.
Biomolecules, 2023
36830579 (PubMed )
Supplement: biomolecules-13-00210-s001.zip › biomolecules-2098784-supplementary.xlsx › Table_S2
Whole-exome Sequencing of Nigerian Prostate Tumors from the Prostate Cancer Transatlantic Consortium (CaPTC) Reveals DNA Repair Genes Associated with African Ancestry.
White JA et al.
Cancer Research Communications, 2022
36922933 (PubMed )
Supplement: crc-22-0136-s01.xlsx › ST9_Somatic_Variants
Custom multi‑tumor next‑generation sequencing panel for routine molecular diagnosis of solid tumors: Validation and results from three‑year clinical use.
Chevrier S et al.
International Journal of Molecular Medicine, 2022
35244186 (PubMed )
Supplement: Supplementary_Data2.xlsx › Feuil1
Structure-based classification predicts drug response in EGFR-mutant NSCLC.
Robichaux JP et al.
Nature, 2021
34526717 (PubMed )
Supplement: 41586_2021_3898_MOESM1_ESM.pdf
Oncogenic mutations within the β3-αC loop of EGFR/ERBB2/BRAF/MAP2K1 predict response to therapies.
Zhang B et al.
Molecular Genetics & Genomic Medicine, 2020
ErbB polymorphisms: insights and implications for response to targeted cancer therapeutics.
Alaoui-Jamali MA et al.
Frontiers in Genetics, 2015
25699077 (PubMed )
Supplement: Table1.PDF
Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis.
Zhang Y et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2012
Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers.
Li C et al.
Plos One, 2011
Select a paper to view details